Hims & Hers Health, Inc. (NYSE:HIMS) Receives $39.83 Consensus Price Target from Analysts

Key Points

• Hims & Hers Health, Inc. has received a consensus recommendation of "Reduce" from analysts, with three rating it as a sell, eight as a hold, and two as a buy.
• Institutional investors have significantly increased their holdings, with Vanguard Group and Farallon Capital Management making notable purchases in the last quarter.
• The company reported a revenue increase of 110.7% year-over-year and exceeded earnings expectations with an EPS of $0.20 for the last quarter.

Shares of Hims & Hers Health, Inc. (NYSE:HIMS - Get Free Report) have been given a consensus rating of "Reduce" by the thirteen brokerages that are presently covering the stock, MarketBeat.com reports. Three investment analysts have rated the stock with a sell rating, eight have assigned a hold rating and two have given a buy rating to the company. The average twelve-month target price among analysts that have updated their coverage on the stock in the last year is $39.83.

Several equities research analysts have recently commented on HIMS shares. Piper Sandler restated a "neutral" rating and issued a $39.00 target price (up previously from $35.00) on shares of Hims & Hers Health in a research note on Tuesday, May 6th. Deutsche Bank Aktiengesellschaft restated a "hold" rating on shares of Hims & Hers Health in a research note on Wednesday, May 7th. UBS Group set a $30.00 target price on shares of Hims & Hers Health in a research note on Monday, June 23rd. Wall Street Zen downgraded shares of Hims & Hers Health from a "buy" rating to a "hold" rating in a research note on Monday. Finally, Morgan Stanley reiterated an "equal weight" rating and set a $40.00 price target on shares of Hims & Hers Health in a research report on Wednesday, June 11th.

Insider Buying and Selling at Hims & Hers Health

In other Hims & Hers Health news, CFO Oluyemi Okupe sold 23,107 shares of the company's stock in a transaction dated Monday, June 23rd. The shares were sold at an average price of $47.25, for a total transaction of $1,091,805.75. Following the transaction, the chief financial officer directly owned 63,222 shares in the company, valued at approximately $2,987,239.50. This represents a 26.77% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO Andrew Dudum sold 128,127 shares of the company's stock in a transaction dated Monday, June 16th. The shares were sold at an average price of $56.76, for a total transaction of $7,272,488.52. Following the transaction, the chief executive officer owned 160,215 shares in the company, valued at approximately $9,093,803.40. The trade was a 44.44% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 737,704 shares of company stock worth $40,644,035. Company insiders own 13.71% of the company's stock.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in HIMS. American Century Companies Inc. lifted its position in Hims & Hers Health by 8.8% during the 4th quarter. American Century Companies Inc. now owns 140,758 shares of the company's stock valued at $3,404,000 after purchasing an additional 11,425 shares during the period. KLP Kapitalforvaltning AS acquired a new position in Hims & Hers Health during the 4th quarter valued at about $861,000. LPL Financial LLC lifted its position in Hims & Hers Health by 1.0% during the 4th quarter. LPL Financial LLC now owns 97,958 shares of the company's stock valued at $2,369,000 after purchasing an additional 980 shares during the period. Vanguard Group Inc. lifted its position in Hims & Hers Health by 11.1% during the 4th quarter. Vanguard Group Inc. now owns 20,257,116 shares of the company's stock valued at $489,817,000 after purchasing an additional 2,020,722 shares during the period. Finally, Mitsubishi UFJ Asset Management Co. Ltd. acquired a new position in Hims & Hers Health during the 4th quarter valued at about $1,356,000. 63.52% of the stock is currently owned by institutional investors and hedge funds.

Hims & Hers Health Stock Performance

Shares of NYSE:HIMS traded down $3.08 on Tuesday, hitting $63.10. The stock had a trading volume of 14,881,747 shares, compared to its average volume of 33,760,211. Hims & Hers Health has a twelve month low of $13.47 and a twelve month high of $72.98. The firm's 50 day moving average price is $53.46 and its 200-day moving average price is $43.79. The company has a market capitalization of $14.12 billion, a price-to-earnings ratio of 91.60, a price-to-earnings-growth ratio of 2.42 and a beta of 2.02.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last issued its earnings results on Monday, May 5th. The company reported $0.20 EPS for the quarter, beating the consensus estimate of $0.12 by $0.08. Hims & Hers Health had a net margin of 9.24% and a return on equity of 22.75%. The company had revenue of $586.01 million for the quarter, compared to the consensus estimate of $535.21 million. During the same quarter in the previous year, the company earned $0.05 EPS. The firm's revenue for the quarter was up 110.7% compared to the same quarter last year. As a group, sell-side analysts predict that Hims & Hers Health will post 0.29 EPS for the current year.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.